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Identity 
Other names: SELP; SeP 
HGNC (Hugo): SEPP1 
Location: 5p12 
Local order: According to NCBI Map Viewer, SEPP1 
gene is located between: LOC100420450, GHR, 
CCDC152 (in telomeric position) and LOC100420275, 
LOC402213 (in centromeric position). 
DNA/RNA 
Description 
The genomic DNA of SEPP1 spans about 12 kb. 
SEPP1 consists of 6 exons. 
Transcription 
3 alternative mRNAs exist encoding 2 different 
isoforms of selenoprotein P. Transcript variants 1 and 2 




SEPP1 belongs to selenoproteins, all of which contain 
selenium in the form of selenocysteine (SeC) and are 
being synthesized in the presence of UGA codon, 
specific stem loop structure in 3' UTR of mRNA called 
SECIS (Selenocysteine Insertion Sequence) and other 
specific factors. Selenoprotein P is a glycoprotein 
present mainly in plasma, where it accounts for 40 - 
65% of total selenium in this blood compartment. 
Plasma SEPP1 concentration is regarded as a functional 
biomarker of human selenium status (Saito and 
Takahashi, 2002; Méplan et al., 2009; Xia et al., 2010). 
Description 
Selenoprotein P consists of 381 amino acids and 
contains ten selenocysteines: nine are located in Sec-
rich C-terminal domain (suggested as the region 
responsible for selenium delivery) and one is present in 
N-terminal domain (region with redox properties 
responsible for enzymatic activity of the protein). Two 
protein isoforms were identified in human plasma: 50 
kDa and 60 kDa (Méplan et al., 2007; Méplan et al., 
2009). 
Expression 
SEPP1 is expressed mainly in the liver, from where it is 
exported to plasma and other tissues. Other organs 
expressing the protein include mainly brain, thyroid 
gland, prostate and mammary gland. Its expression has 
been found to be significantly reduced in cancer, 
including prostate, colon and lung (Gonzalez-Moreno 
et al., 2010). 
SEPP1 expression is downregulated by different 
cytokines (Al-Taie et al., 2002). Also hepatic factors 
such as insulin and glucocorticoids may regulate 




It is supposed that SeP is responsible for the transport 
of selenium within body and delivering the 
microelement to the cells. In brain and testis (organs, in 
which selenium plays an important role), SEPP1 uptake 
is mediated by apolipoprotein E receptor-2 (apoER2). 
In kidneys, the uptake is regulated by another receptor, 
called megalin (Burk and Hill, 2009) (figure 1). 
Additionally, SEPP1 is involved in the reduction of
oxidative stress due to its redox properties (Saito et al., 
2004). 
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Figure 1. SEPP1 in selenium homeostasis and transport to the 
testis, brain and kidney. Whole - body selenium excretion is 
controlled by selenium excretion in the urine. SEPP1 and 
selenium excretory metabolites compete for metabolically 
available selenium in the liver, determining urinary selenium 
excretion. The lipoprotein receptor apoER2 binds SEPP1 and 
facilitates its uptake into the testis where selenium is 
incorporated into spermatozoa. ApoER2 also maintains brain 
selenium. SEPP1 is filtered by the kidney into the glomerular 
filtrate and binds to megalin in the brush border of proximal 
convoluted tubules. Those cells endocytose the SEPP1 bound 
to megalin and presumably use its selenium to synthesize 
plasma glutathione peroxidase (GPx3) (adapted from Burk and 
Hill, 2009, with the authors' permission). 
Homology 
SEPP1 is conserved in chimpanzee, dog, cow, mouse, 
rat and zebrafish. 
Mutations 
Note 
No mutations in SEPP1 gene have been identified yet.  
Genetic variations: several SNPs were identified.  
Most often studied polymorphisms within SEPP1:  
- Ala234Thr (rs 3877899) - associated with a G/A 
transition at position 24731 of mRNA, with the amino 
acid change from alanine to threonine in the codon 234.
This polymorphism influences the SePP1 isoform 
pattern. Using Western blot analysis, it was shown that
in the individuals possessing Ala/Ala genotype, 60 kDa 
protein was a dominating isoform, whereas in those 
with Ala/Thr genotype, the band for 50 kDa isoform 
was stronger (Thr/Thr genotype was not analyzed in 
this study). It was also observed, that within Ala/ 
and Ala/Thr individuals, males had less 60 kDa isoform 
as compared to females (Méplan et al., 2009).  
- r25191g/a (rs 7579) - G/A transition at position 25191 
within 3'-UTR. Similarly as rs 3877899 SNP, this SNP  
 
 
seems to influence the proportion of SEPP1 isoforms. 
Individuals with GG genotype had lower proportion of 
60 kDa isoform as compared to those with GA or AA 
genotype (Méplan et al., 2009).  
- (TC)5/(TC)3 repeats at promoter region. It was shown 
in in vitro study that TC3 allele reduced the promoter 
activity of reporter gene constructs in HepG2 cells (Al-




Persson-Moschos et al. (2000) conducted a nested case 
control study, in which 12500 middle aged men were 
enrolled and the follow up time was between 1974-
1988. Within the studied cohort, SEPP1 plasma 
concentration was significantly lower in the indiviuals 
who were diagnosed with cancer during the follow up 
(and whose plasma samples were available for analysis, 
n=302) as compared to control subjects (n=604). The 
authors of this study suggested that plasma SEPP1 level 
is associated with higher risk of cancer of respiratory 
and digestive tract. 
Colon cancer 
Note 
Decreased expression of SePP1 mRNA was observed 
in colorectal cancer tissue as compared with normal 
colon mucosa (Al-Taie et al., 2004).  
The study of 196 cases and 239 controls revealed no 
association between polymorphism at SEPP1 promoter 
region (TC)5/(TC)3 repeats and colon cancer risk. 
However, authors of the study observed genomic 
instability of Poly-(T)-single nucleotide repeat motif 
present in the SEPP1 promoter sequence in the colon 
cancer tissues as compared to normal colon mucosa 
from the same patients. This instability was observed in 
10 out of 51 cases possessing two (TC)5 alleles (no 
instability was observed in 5 cases with (TC)5/(TC)3 
genotype; (TC)3/(TC)3 homozygotes were not present 
in the studied group) (Al-Taie et al., 2002).  
Other study, involving 772 cases and 777 controls, 
revealed that four SNPs within SEPP1 gene were 
significantly associated with risk of colorectal 
adenoma. The SNPs were: SEPP1 -4166G, 
rs12055266, rs3797310, rs2972994 (Peters et al., 
2008).  
In the study by Méplan et al. (2009), in which plasm  
samples from 20 colon cancer patients and 21 healthy 
individuals were analyzed, significantly lower 
proportion of 60 kDa isoform was observed in cases 
with SEPP1 GG genotype of rs 3877899 as compared 
to controls with the same genotype. Similar 
(statistically significant) difference between cases and 
controls was also indicated within individuals 
possessing GA genotype of rs7579. 
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Prostate cancer 
Note 
Expression of SEPP1 mRNA was down regulated in 
human prostate tumours as well as prostate carcinoma 
cell lines (Calvo et al., 2002).  
Further investigation revealed that down-regulation of 
SEPP1 in prostate cancer cells leads to an increased 
production of reactive oxygen species (Gonzalez-
Moreno et al., 2010).  
In the study conducted on 90 males with prostate 
cancer and 100 control men, it was observed that 
protein's concentration measured in serum was lower in 
cases as compared to controls (Meyer et al., 2009). 
The interaction between polymorphic variants of SePP1 
and SOD2 genes in prostate cancer risk was found by 
Cooper et al. (2008). According to the results based on 
CAPS study (Prostate CAncer in Sweden), males being 
homozygous for SEPP1 Ala234 allele (rs 3877899) and 
who possessed at least one SOD2 Ala16 allele (rs 
4880), were at significantly higher risk of prostate 
cancer.  
In a study of 248 prostate cancer cases and 492 
controls, borderline significant association between 
prostate cancer risk and SEPP1 polymorphism (rs 
7579) was found (Steinbrecher et al., 2010). 
References 
Persson-Moschos ME, Stavenow L, Akesson B, Lindgärde F. 
Selenoprotein P in plasma in relation to cancer morbidity in 
middle-aged Swedish men. Nutr Cancer. 2000;36(1):19-26 
Al-Taie OH, Seufert J, Mörk H, Treis H, Mentrup B, Thalheimer 
A, Starostik P, Abel J, Scheurlen M, Köhrle J, Jakob F. A 
complex DNA-repeat structure within the Selenoprotein P 
promoter contains a functionally relevant polymorphism and is 
genetically unstable under conditions of mismatch repair 
deficiency. Eur J Hum Genet. 2002 Sep;10(9):499-504 
Calvo A, Xiao N, Kang J, Best CJ, Leiva I, Emmert-Buck MR, 
Jorcyk C, Green JE. Alterations in gene expression profiles 
during prostate cancer progression: functional correlations to 
tumorigenicity and down-regulation of selenoprotein-P in 
mouse and human tumors. Cancer Res. 2002 Sep 
15;62(18):5325-35 
Saito Y, Takahashi K. Characterization of selenoprotein P as a 
selenium supply protein. Eur J Biochem. 2002 
Nov;269(22):5746-51 
Al-Taie OH, Uceyler N, Eubner U, Jakob F, Mörk H, Scheurlen 
M, Brigelius-Flohe R, Schöttker K, Abel J, Thalheimer A, 
Katzenberger T, Illert B, Melcher R, Köhrle J. Expression 
profiling and genetic alterations of the selenoproteins GI-GPx 
and SePP in colorectal carcinogenesis. Nutr Cancer. 
2004;48(1):6-14 
Saito Y, Sato N, Hirashima M, Takebe G, Nagasawa S, 
Takahashi K. Domain structure of bi-functional selenoprotein 
P. Biochem J. 2004 Aug 1;381(Pt 3):841-6 
Méplan C, Crosley LK, Nicol F, Beckett GJ, Howie AF, Hill KE, 
Horgan G, Mathers JC, Arthur JR, Hesketh JE. Genetic 
polymorphisms in the human selenoprotein P gene determine 
the response of selenoprotein markers to selenium 
supplementation in a gender-specific manner (the SELGEN 
study). FASEB J. 2007 Oct;21(12):3063-74 
Cooper ML, Adami HO, Grönberg H, Wiklund F, Green FR, 
Rayman MP. Interaction between single nucleotide 
polymorphisms in selenoprotein P and mitochondrial 
superoxide dismutase determines prostate cancer risk. Cancer 
Res. 2008 Dec 15;68(24):10171-7 
Peters U, Chatterjee N, Hayes RB, Schoen RE, Wang Y, 
Chanock SJ, Foster CB. Variation in the selenoenzyme genes 
and risk of advanced distal colorectal adenoma. Cancer 
Epidemiol Biomarkers Prev. 2008 May;17(5):1144-54 
Speckmann B, Walter PL, Alili L, Reinehr R, Sies H, Klotz LO, 
Steinbrenner H. Selenoprotein P expression is controlled 
through interaction of the coactivator PGC-1alpha with FoxO1a 
and hepatocyte nuclear factor 4alpha transcription factors. 
Hepatology. 2008 Dec;48(6):1998-2006 
Burk RF, Hill KE. Selenoprotein P-expression, functions, and 
roles in mammals. Biochim Biophys Acta. 2009 
Nov;1790(11):1441-7 
Méplan C, Nicol F, Burtle BT, Crosley LK, Arthur JR, Mathers 
JC, Hesketh JE. Relative abundance of selenoprotein P 
isoforms in human plasma depends on genotype, se intake, 
and cancer status. Antioxid Redox Signal. 2009 
Nov;11(11):2631-40 
Meyer HA, Hollenbach B, Stephan C, Endermann T, 
Morgenthaler NG, Cammann H, Köhrle J, Jung K, Schomburg 
L. Reduced serum selenoprotein P concentrations in German 
prostate cancer patients. Cancer Epidemiol Biomarkers Prev. 
2009 Sep;18(9):2386-90 
Gonzalez-Moreno O, Boque N, Redrado M, Milagro F, 
Campion J, Endermann T, Takahashi K, Saito Y, Catena R, 
Schomburg L, Calvo A. Selenoprotein-P is down-regulated in 
prostate cancer, which results in lack of protection against 
oxidative damage. Prostate. 2010 Nov 17; 
Hurst R, Armah CN, Dainty JR, Hart DJ, Teucher B, Goldson 
AJ, Broadley MR, Motley AK, Fairweather-Tait SJ. Establishing 
optimal selenium status: results of a randomized, double-blind, 
placebo-controlled trial. Am J Clin Nutr. 2010 Apr;91(4):923-31 
Méplan C, Hughes DJ, Pardini B, Naccarati A, Soucek P, 
Vodickova L, Hlavatá I, Vrána D, Vodicka P, Hesketh JE. 
Genetic variants in selenoprotein genes increase risk of 
colorectal cancer. Carcinogenesis. 2010 Jun;31(6):1074-9 
Steinbrecher A, Méplan C, Hesketh J, Schomburg L, 
Endermann T, Jansen E, Akesson B, Rohrmann S, Linseisen 
J. Effects of selenium status and polymorphisms in 
selenoprotein genes on prostate cancer risk in a prospective 
study of European men. Cancer Epidemiol Biomarkers Prev. 
2010 Nov;19(11):2958-68 
Xia Y, Hill KE, Li P, Xu J, Zhou D, Motley AK, Wang L, Byrne 
DW, Burk RF. Optimization of selenoprotein P and other 
plasma selenium biomarkers for the assessment of the 
selenium nutritional requirement: a placebo-controlled, double-
blind study of selenomethionine supplementation in selenium-
deficient Chinese subjects. Am J Clin Nutr. 2010 
Sep;92(3):525-31 
This article should be referenced as such: 
Jablonska E, Gromadzinska J, Reszka E, Wasowicz W. 
SEPP1 (selenoprotein P, plasma, 1). Atlas Genet Cytogenet 
Oncol Haematol. 2011; 15(10):887-889. 
